Medicare Coverage Guide for Pluvicto Treatment

What Pluvicto Is and Why Medicare Coverage Matters

Pluvicto (lutetium Lu-177 gozetotide) is a type of cancer treatment that combines a radioactive element with a targeting molecule. It's designed for men with a specific form of advanced prostate cancer that has spread beyond the prostate gland. The treatment works by delivering radiation directly to cancer cells that express a protein called PSMA, which stands for prostate-specific membrane antigen. This targeted approach means the radiation concentrates where cancer cells are located rather than spreading throughout the entire body.

Learn How Doxo Works for Bill Payment →

The FDA approved Pluvicto in June 2023, making it a relatively new option in the prostate cancer treatment landscape. Because it's new and involves specialized nuclear medicine technology, understanding how Medicare covers it matters significantly for people on Medicare who might benefit from this treatment. The cost of Pluvicto can run into tens of thousands of dollars per treatment cycle, so knowing what your coverage situation might look like is an important step in planning your cancer care.

Medicare's coverage of Pluvicto is notable because the program moved relatively quickly to cover this new treatment. The Centers for Medicare & Medicaid Services (CMS) determined that Pluvicto met the criteria for coverage under the Medicare benefit for nuclear medicine procedures. However, coverage details vary depending on whether you have Original Medicare or a Medicare Advantage plan, which is crucial information to understand before pursuing treatment.

Practical takeaway: Before exploring Pluvicto as a treatment option, confirm with your oncologist that you have the specific type of prostate cancer this treatment targets (PSMA-positive metastatic castration-resistant prostate cancer). This medical confirmation is your starting point for any coverage conversation.

Original Medicare Coverage: How It Works for Pluvicto

Original Medicare (Part A and Part B) covers Pluvicto when it's administered in an outpatient hospital setting or an approved nuclear medicine facility. The drug itself, the administration of the treatment, and related imaging and monitoring procedures fall under Medicare's coverage framework. When you receive Pluvicto through Original Medicare, you're typically looking at coverage through Part B, which covers outpatient services including chemotherapy and other cancer treatments.

Learn About Erie County Water Bill Payment Options →

Under Original Medicare, you'll encounter the standard cost-sharing structure. This means you'll likely pay 20 percent of the Medicare-approved amount for the treatment after you've met your Part B deductible. The Part B deductible for 2024 is $240 (this amount can change yearly). Once you've paid this deductible, Medicare covers 80 percent of the approved cost, and you pay the remaining 20 percent coinsurance. It's important to note that this coinsurance continues for each Pluvicto treatment session you receive.

The Medicare-approved amount for Pluvicto can be substantial. While individual pricing varies based on geographic location and the facility where you receive treatment, the approved amount typically ranges from $30,000 to $50,000 per treatment cycle, though this may vary. Your actual out-of-pocket cost depends on the specific approved amount in your region and whether your treatment facility accepts Medicare assignment (meaning they accept the Medicare-approved amount as payment in full for the covered service).

You should also factor in related costs that Medicare covers separately. Before and after Pluvicto treatment, you'll typically need imaging studies like PET scans to monitor your response and check for side effects. These imaging services are generally covered by Medicare, though they follow their own cost-sharing rules. Lab work and office visits with your oncologist during treatment are also covered services with their own coinsurance amounts.

Practical takeaway: Contact your treatment facility's billing department and ask them to provide the specific Medicare-approved amount for Pluvicto at their location. Once you know this number, you can calculate your 20 percent coinsurance obligation per treatment. Then multiply by the number of treatments your doctor recommends (typically four to six treatments over several months) to get a sense of your total out-of-pocket responsibility.

Medicare Advantage Plans and Pluvicto Coverage: What to Know

Medicare Advantage plans (Part C plans) offer an alternative to Original Medicare for your hospital and medical coverage. These plans are run by private insurance companies and must cover at least what Original Medicare covers, but they often do so with different costs and requirements. When it comes to Pluvicto, your specific plan's coverage depends entirely on that plan's design and negotiated rates with providers.

Learn How to Pay Your Carroll Electric Bill →

Most major Medicare Advantage plans do cover Pluvicto, but the specifics matter tremendously. Some plans may require prior authorization before you can begin treatment, meaning your oncologist must submit paperwork to the plan for approval before your first infusion. This isn't a denial—it's a verification step that the treatment meets the plan's medical necessity criteria. In most cases, prior authorization for Pluvicto is approved, but the process typically takes a few days to a couple of weeks, so plan accordingly with your medical team.

Your out-of-pocket costs with a Medicare Advantage plan may be lower, higher, or structured differently than Original Medicare. Some plans cover Pluvicto with a flat copay per treatment (ranging from $0 to $500 depending on the plan), while others use coinsurance similar to Original Medicare. Many plans cap your annual out-of-pocket maximum, which Original Medicare does not. This means if your Pluvicto treatments and related services push you to your plan's out-of-pocket maximum (typically between $5,000 and $10,000 annually), Medicare covers additional services at no cost for the rest of that year.

You'll also need to understand your plan's network requirements. Some Medicare Advantage plans require you to use specific cancer treatment centers or hospitals for coverage of Pluvicto, while others offer more flexibility. If you receive treatment outside your plan's network without authorization, you could face much higher costs or even no coverage at all. This is why reviewing your plan's provider directory for oncology services is a critical first step.

Practical takeaway: Find your Medicare Advantage plan's member services phone number on your insurance card. Call and ask three specific questions: (1) Is Pluvicto covered under my plan? (2) What is my coinsurance or copay per treatment? (3) Which cancer treatment centers or hospitals can I use? Write down the answers along with the date and time of your call.

Prior Authorization and Getting Pluvicto Approved by Medicare

Even though Medicare covers Pluvicto, your oncologist typically needs to go through a prior authorization process before your first treatment. This might sound like a barrier, but it's a standard step that usually results in approval without major complications. Prior authorization means your doctor's office submits documentation to Medicare (if you have Original Medicare) or your Medicare Advantage plan showing that you meet specific criteria for receiving this treatment.

How to Pay Your SVEC Electric Bill Online →

The documentation typically includes your medical records showing your diagnosis of metastatic castration-resistant prostate cancer with PSMA-positive expression. You'll need imaging results that confirm your cancer has spread (metastatic disease), and your doctor will provide evidence that you've already tried standard treatments without adequate response. Medicare and Medicare Advantage plans want confirmation that Pluvicto is medically necessary for your specific situation, not just that you have prostate cancer.

The prior authorization process usually takes between 3 to 7 business days for Original Medicare, though some Medicare Advantage plans may work faster or slower depending on their internal procedures. Your oncologist's office manages most of this paperwork on your behalf. However, it's worth calling your doctor's prior authorization specialist to confirm they've submitted everything and to ask when you might expect approval. Having a copy of the authorization letter or approval notification is helpful to keep for your records.

In rare cases, prior authorization may be initially denied. This doesn't mean you can't receive Pluvicto—it means Medicare or your plan needs more information. Your oncologist can submit additional documentation, medical literature, or request a peer-to-peer review where your doctor discusses your case directly with a physician at Medicare or your plan. Most denials are successfully appealed with proper documentation. Your doctor's office should handle the appeal process, but you can also ask to speak with your plan's patient advocate if you're concerned about the timeline.

Practical takeaway: Ask your oncology office which staff member is handling your prior authorization and get their direct contact information. Follow up with them one week after your doctor submits the paperwork. This simple check-in often